Bayer Launches Phase III Trial Testing Mirena IUD for Precancerous Uterine Condition with No Approved Treatments
核心洞察
Bayer has initiated the SUNFLOWER Phase III clinical trial to evaluate Mirena's 52mg levonorgestrel-releasing intrauterine system as a treatment for nonatypical endometrial hyperplasia (搜索) (NAEH), a precancerous uterine condition.
NAEH affects 121-270 per 100,000 women annually and currently has no approved medical treatments, representing a significant unmet medical need.
The study will compare Mirena against oral progestin (搜索) therapy in 207 patients across 90 centers in three countries, with completion expected in approximately 18 months.
Bayer has announced the initiation of a global Phase III clinical trial to test its flagship intrauterine device Mirena as a treatment for nonatypical endometrial hyperplasia (搜索) (NAEH), a precancerous condition affecting the uterine lining that currently has no approved medical therapies available.
The SUNFLOWER study (Study of Understanding NAEH-treatment eFficacy of LevonOrgestrel–IUS in Women Electing non-suRgical options) will evaluate the efficacy and safety of Bayer's 52mg levonorgestrel-releasing intrauterine system (LNG-IUS) compared to oral progestin (搜索) therapy in treating NAEH.
Addressing a Critical Unmet Medical Need
Nonatypical endometrial hyperplasia (搜索) represents an abnormal thickening of the uterine lining caused by an imbalance between estrogen and progesterone levels. The condition is classified as nonatypical because the endometrial cells do not show signs of cancer, though it can progress to more serious forms if left untreated.
The annual incidence of NAEH ranges from 121 to 270 per 100,000 women, depending on geography, age, and menopause status. The condition can present asymptomatically or cause heavy or abnormal bleeding, including bleeding after menopause. Without treatment, NAEH may progress to atypical forms or even uterine cancer (搜索).
"Having a leading position in global women's health we are committed to advance science focusing on innovative options to address the unmet medical need of women globally," said Christian Rommel, Ph.D., head of research and development at Bayer's Pharmaceuticals Division. "With this new Phase III study, we are now expanding our broad clinical development program for intrauterine systems to be able to support women suffering from nonatypical endometrial hyperplasia (搜索) with an effective treatment."
Study Design and Timeline
The SUNFLOWER trial aims to enroll 207 patients at approximately 90 centers across three countries. The study is anticipated to take around 1.5 years until completion, positioning it as a pivotal trial for establishing a new treatment paradigm for NAEH.
Previous studies testing the 52mg LNG-IUS for NAEH treatment have indicated good response rates, attributed to the type of hormone present in the device and its direct effect inside the uterus. These earlier investigations suggest the system helps restore the endometrium to a normal state in most cases.
Mirena's Mechanism and Current Applications
Mirena is a T-shaped device containing 52mg of synthetic levonorgestrel that continuously releases small amounts of the hormone directly into the uterus once placed. As a long-acting reversible contraceptive (LARC), it can be removed at any time by a healthcare provider if a woman's plans change.
The device's current approved indications, which may vary by country, include contraception, idiopathic menorrhagia/heavy menstrual bleeding (搜索), endometrial protection during estrogen therapy for menopause, and dysmenorrhea (搜索). Mirena is currently available in more than 120 countries worldwide.
Strategic Expansion in Women's Health
This Phase III trial represents Bayer's continued investment in addressing unmet medical needs in women's healthcare. The company has positioned itself as a global leader in this space, offering a comprehensive range of short- and long-acting birth control methods as well as therapies for menopause management and gynecological diseases.
The SUNFLOWER study's focus on NAEH treatment aligns with Bayer's broader commitment to expanding treatment choices for women worldwide, particularly in areas where current therapeutic options are limited or non-existent.